GlassScriptPhysician profile
Quoc L Vo
NPI 1063479665
$560.98
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Neuromusculoskeletal Medicine & OMM
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $20.31 · 2021: $212 · 2022: $20.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $127.20 | 2019 | |
| Lilly USA, LLC | $86.87 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $71.22 | 2019 | |
| Abbvie INC. | $49.64 | 2021 | |
| Biodelivery Sciences International, INC. | $44.52 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $27.44 | 2019 | |
| Boston Scientific Corporation | $26.68 | 2019 | |
| Amgen INC. | $25.14 | 2021 | |
| Neuronetics, INC. | $21.85 | 2019 | |
| Collegium Pharmaceutical, INC. | $21.20 | 2019 | |
| Bausch Health US, LLC | $20.31 | 2020 | |
| Hikma Pharmaceuticals USA | $19.70 | 2021 | |
| Lundbeck LLC | $19.21 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quoc Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.